- Home
- WDI vs AGMB Comparison
WDI vs AGMB Comparison
Compare WDI & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDI | AGMB |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.5M | 576.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | WDI | AGMB |
|---|---|---|
| Price | $11.69 | $6.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $37.67 |
| AVG Volume (30 Days) | ★ 386.4K | 155.6K |
| Earning Date | 01-01-0001 | 11-23-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.34 | $6.46 |
| 52 Week High | $14.51 | $17.82 |
Technical Indicators
Market Signals| Indicator | WDI | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 32.39 |
| Support Level | $11.50 | N/A |
| Resistance Level | $11.98 | $9.55 |
| Average True Range (ATR) | 0.14 | 0.86 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 59.83 | 12.92 |
Price Performance
Historical ComparisonAbout WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.